Inflammation in stroke: initial CRP levels can predict poor outcomes in endovascularly treated stroke patients

Background and purpose: Inflammation has been linked to poor prognoses in cardio- and cerebrovascular conditions. As it is known to increase after ischemia, C-reactive protein (CRP) may serve as a surrogate for systemic inflammation and thus be a hallmark of increased tissue vulnerability. The question arises whether CRP in the acute phase of ischemic stroke, prior to mechanical thrombectomy (MT), might help predict outcomes.

Materials and methods: A single-center collective of patients with large-vessel occlusion, who were treated via MT, was analyzed in this observational case–control study. Univariate and multivariate models were designed to test the prognostic value of inflammatory markers (CRP and leukocytosis) in predicting clinical outcomes (modified Rankin score >2) and all-cause mortality 90 days after MT.

Results: A total of 676 ischemic stroke patients treated with MT were included. Of these, 313 (46.3%) showed elevated CRP levels (≥5 mg/l) on admission. Poor clinical outcome and mortality at 90 days occurred in 113 (16.7%) and 335 (49.6%) patients and significantly more frequently when initial CRP levels were elevated [213 (64.5%) vs. 122 (42.1%), p < 0.0001, and 79 (25.2%) vs. 34 (9.4%), p < 0.0001, respectively]. CRP levels were highly predictive for impaired outcomes, especially in patients with atrial fibrillation, in both univariate and multivariate models. Interestingly, patients with initially elevated CRP levels also showed more pronounced increases in CRP post-MT.

Conclusion: Poor outcome and death occur significantly more often in stroke patients with elevated CRP levels before MT. Our findings suggest that stroke patients with atrial fibrillation and elevated inflammatory markers are of particular risk for poor outcomes.

Introduction

Outcomes in ischemic stroke have improved greatly over the last decades in large part due to the wider availability of specialized stroke units as well as the establishment of endovascular therapy as the standard of care for patients who present with acute large-vessel occlusions (LVOs) (1–5). In recent years, the indication for mechanical thrombectomy (MT) has been extended, e.g., to later time windows and smaller vessels, with procedural techniques being continuously improved (6, 7).

Nonetheless, ischemic stroke continues to pose a significant burden as it remains a main cause of morbidity and mortality worldwide and accounts for a large proportion of quality-adjusted life years lost (8). Many multiparametric models for predicting good clinical outcomes after endovascularly treated stroke include obvious confounders, such as time to treatment or the success of revascularization. However, despite successful reperfusion in good time windows, the long-term clinical trajectory is not always as favorable as expected. Some mechanisms conveying adverse outcomes remain ill-explained, especially as complex markers such as neuronal damage serum proteins may also play an important and yet poorly understood role in influencing outcomes (9, 10).

Pro-inflammatory systemic environments have recently been identified to independently predict poor outcomes in a panoply of conditions, from ischemic heart disease to carotid atherosclerosis progression, as well as ischemic stroke treated via intravenous thrombolysis (11–15). Moreover, the more delayed cellular inflammation conveyed by leukocytosis has been shown to correlate with poor outcome after MT (16). All these observations are hinting at the role that neuro-inflammation could have in post-ischemic brain remodeling.

High-sensitivity C-reactive protein (CRP) is an accessible serum protein known to be a reliable marker for systemic inflammation but also mediate pro-inflammatory downstream cascades, making it a suitable candidate to assess the level of intra-individual inflammation (17, 18). Moreover, the observation that most stroke patients showcase high-CRP levels is noteworthy given that activation of the secondary complement system and subsequent secondary brain damage through CRP has been shown experimentally (19).

It remains unclear whether CRP is elevated in response to ischemia-induced neuronal damage or whether pro-inflammatory mechanisms themselves are causing a time-delayed injury of ischemic brain tissue, analogous to phenomena seen after thermic tissue shock (20). As inflammatory markers have been associated with atrial fibrillation and thromboembolic complications, it may also be conceivable that inflammation influences the pathogenesis of ischemic stroke (21).

Our assumption is that CRP levels in the very-early stage of ischemic stroke could be a hallmark of systemic inflammation and increase the ad hoc vulnerability of the brain tissue to ischemic stress as well as promote subsequent neuronal damage through mediation of a post-ischemic ischemia-inflammation cascade. Identification of this association would add to current knowledge in stroke care, identify patients at risk benefitting from the most intensified and early anti-inflammatory therapy regimes, and advocate for future interventional studies (22).

To address those questions, the present study aims to investigate an association of inflammatory blood markers (CRP and leukocytosis) with neurological outcome and mortality in a large cohort of ischemic stroke patients with LVO treated with MT.

Methods

Study design

Prospectively collected clinical, interventional, and outcome parameters of a large collective of endovascular treated stroke patients in a comprehensive stroke center were analyzed for this retrospective single-center case–control study. The association of inflammatory markers with outcome parameters was tested as outcomes.

The study was approved by the local ethics committee, and the need for patient consent was waived. The observational, retrospective study design did not interfere with the routine clinical workflow and did not influence therapeutic decision-making. The results were reported in adherence to the STROBE statement guidelines.

Study population

This retrospective, single-center study included all consecutive patients with ischemic stroke due to LVO who were admitted at a single comprehensive stroke center and treated by MT between January 2017 and March 2021 (n = 1,012).

Patients with an unclear onset of symptoms (wake-up stroke) or a concurring cause of infection at both admission or during the first 7 days of hospital stay were excluded. Furthermore, we only included patients for whom inflammatory serum markers on admission and outcome data at 90-day follow-up were available.

The prospectively collected clinical and imaging data were retrospectively analyzed. Basic demographic, clinical, and interventional data of patients were gathered. NIHSS-certified neurologists assessed the National Institutes of Health Stroke Scale (NIHSS) score at the time of admission and discharge. Substantial neurological improvement (SNI) was defined as the difference between admission and discharge, with an NIHSS score of ≥8 or a discharge NIHSS score of ≤ 1.

The mRS score was used to measure disability premorbid at discharge and at follow-up, while a poor clinical outcome in the 90-day follow-up was defined as mRS > 2.

Outcome values such as mRS and mortality in the follow-up were assessed either through routine follow-up in-house visits or, if the patient was not present for various reasons, by phone call through an experienced study nurse.

Stroke pathogeneses were determined according to the international TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification based on diagnostic and clinical information available for each patient (23). Further variables that are relevant for the present study included the presence of atrial fibrillation as well as documentation of cardiovascular risk factors such as active smoking, hypertension, hyperlipidemia, and diabetes mellitus. Pre-existing treatment with platelet-inhibiting drugs or lipid-lowering therapies was documented. Administration of pre-interventional intravenous tissue-type plasminogen activator (tPA) thrombolysis was assessed. At the end of the endovascular procedure, successful recanalization was defined as mTICI 2b-3 (24). Time of symptom onset, time of admission, time of reperfusion, and corresponding procedure times were taken from the existing database. Time to admission was defined between symptom onset and admission. Reperfusion time was defined between symptom onset and mTICI ≥ 2b. In cases, when recanalization was not successful (TICI < 2b), the control series after the last maneuver was used as the time endpoint.

Assessment of inflammation markers

In patients with elevated CRP levels (defined as >5 mg/l), hospital records were retrospectively screened to determine whether any cause of infection was apparent prior to stroke onset or became uncovered during the acute-care hospital stay.

Levels of CRP and leukocyte counts were determined from the emergency blood panel taken upon referral, prior to MT, as well as blood panels drawn within the first 7 days after MT. This allowed for the analysis of three models: (i) outcome prediction based on the level of inflammatory markers at the time of admission, (ii) subgroup analysis in patients for whom serum inflammatory markers were available in the hyper-acute phase (< 4 h after symptom onset), with an aim to exclude the effects of CRP release secondary to brain ischemia, and (iii) subgroup analysis of prognostic effects linked to the CRP dynamics in the first 7 days after MT.

Imaging analysis

The volume of brain tissue necrosis at the time of admission was quantitatively estimated from CT perfusion (CTP) data [RAPID software (iSchemaView, Menlo Park, CA, USA)] (25). Acquisition of CTP is part of an in-house stroke neuroimaging standard operating procedure and was thus available for all patients, irrespective of the timing of symptom onset. The infarct core at admission was defined as the volumetric sum of voxels showcasing cerebral blood flow < 30% to the contralateral hemisphere. Alberta Stroke Program Early CT Score (ASPECTS) was automatically assessed from admission CT imaging (iSchemaView, Inc., Menlo Park, CA, USA) for patients with occlusion of the MCA.

Statistical analysis

Continuous and categorical variables are given as mean and standard deviation (SD) and frequencies if not indicated otherwise. Variables were compared using the Mann–Whitney U-test and unpaired student t-test, as appropriate. Receiver operator characteristic (ROC) curve analysis was used to determine the association of continuously measured CRP levels and outcomes. The Youden index was subsequently determined to find optimal cutoff values for CRP levels. The relationship between outcomes and elevated CRP levels (defined cutoff of 5 mg/L according to in-house laboratory standards) was expressed as an odds ratio (OR), with a corresponding 95% confidence interval (CI) through logistic regression.

To correct for confounders, adjustments for the impact of age, sex, atrial fibrillation, hypertension, diabetes mellitus, estimated CTP infarct volume, premorbid mRS levels, and reperfusion success were made with multiple logistic regression. A moderation analysis was performed to check the interaction of the subgroups with/without atrial fibrillation on the association between CRP levels and outcomes under consideration of the abovementioned covariates (26).

Statistical analyses were performed using IBM SPSS Statistics version 28.0.0. for macOS (IBM, USA).

Results

Patient demographics and clinical data

Over the retrieval period, 1,012 patients were referred for MT of a LVO. Of these, 62 were lost to follow-up. Furthermore, 274 patients were either “wake-up” strokes or had an infection either pre-existing or developing within the first 7 days of in-clinic stay (mean diagnosis at 4.3 days post-MT) and were thus excluded, leading to a study collective of 676 patients at a mean age of 74 ± 13 years (48.5% men). Mean CRP levels at admission were 1.7 ± 3.2 mg/l and elevated in 313 patients (46.3%). Patients with elevated CRP levels experienced higher frequencies of atrial fibrillation (57.5 vs. 41.3%, p < 0.001), hypertension (64.9 vs. 60.6%, p = 0.01), and diabetes mellitus (26.2 vs. 16.8%, p = 0.003), as well as leukocyte counts (10.46 ± 6.79 G/l vs. 9.79 vs. 3.39 G/l, p < 0.001). Apart from this, both groups had similar clinical profiles (Table 1).

TABLE 1

Table 1. Patient demographics for the study cohort and dichotomized according to CRP levels.

Stroke- and MT-related parameters

In descending frequency, the most commonly occluded vessels were middle cerebral artery (n = 384, 56.8%), distal segment of the internal carotid artery (n = 73, 10.8%), combination of >1 occluded intracranial vessel (n = 59, 8.7%), tandem occlusions (n = 53, 7.8%), basilar artery (n = 44, 6.5%), proximal segment of the internal carotid artery (n = 37, 5.5%), posterior cerebral artery (n = 11, 1.6%), anterior cerebral artery (n = 8, 1.2%), and the vertebral artery (n = 7, 1.0%). Symptom severity was moderate on average with mean NIHSS scores of 13 ± 6.8. Counting from the onset of clinical symptoms, the time to admission (52 ± 41 min vs. 58 ± 72 min, p = 0.19) and the time to reperfusion (191 ± 144 min vs. 189 ± 146 min, p = 0.79) were similar for both groups. I.v. thrombolysis was performed significantly less frequently in the cohort with elevated CRP levels (37.1 vs. 47.7%, p = 0.006). Moreover, patients with elevated CRP levels demonstrated larger estimated infarct cores on CTP (24.2 ± 41.2 ml vs. 17.3 ± 29.4 ml, p = 0.014) albeit comparable infarct areas as estimated by ASPECTS (4.95 ± 4.0 vs. 5.0 ± 4.2, p = 0.0.87) in the subgroup with MCA occlusion. Moreover, the thrombectomy results were better in patients whose initial CRP levels were elevated with 90.4 % (against 84.6%, p = 0.02) of final thrombectomy scores being mTICI 2b or better.

Outcomes

After 90 days of thrombectomy, a total of 113 patients (16.7%) were deceased with death occurring significantly more often in patients showcasing high-CRP levels ad initio (25.2 vs. 9.4%, p < 0.0001) (Figure 1). Median mRS after 90 days was 3 (IQR: 2; 5) and at a disadvantage in the high-CRP group with 4 (2; 6) vs. 2 (1; 4) (p < 0.0001). Brain hemorrhage up until the day of discharge, as verified by CT or MR imaging, was noted in a total of 15/460 patients (3.3%) for whom postprocedural imaging was available and at comparable rates in both groups (3.7 vs. 3.0%, p = 0.69). NIHSS values at discharge were available for 460/676 patients. A SNI at discharge could be noted in 206 of these patients. The frequency of SNI showed a trend to be higher in patients with normal initial CRP values (141/297, 47.5%) than in patients with elevated initial CRP values (65/163, 39.9%) (p = 0.11). Refer to Table 2 for a detailed outcome analysis.

FIGURE 1

Figure 1. Relative occurrence of death or poor clinical outcome 90 days after mechanical thrombectomy, dichotomized according to initial CRP levels.

TABLE 2

Table 2. Occurrence of primary outcomes 90 days after mechanical thrombectomy, as well as secondary endpoint occurrence ICH and re-occlusion, as verified by CT or MRI, up until discharge.

Association of inflammatory markers with outcomes

Odds ratios for death or poor outcome (mRS > 2) 90 days after thrombectomy have been calculated for all investigated parameters in univariate models, as shown in Figures 2A, B. In the decreasing order, CTP-estimated infarct volumes, elevated initial CRP levels, poor thrombectomy results (TICI < 2b), and pre-existing neurological impairments (mRS > 0) showed the highest association with poor outcomes after 90 days. On the other hand, poor thrombectomy outcomes (TICI < 2b), elevated CRP levels, CTP-estimated infarct volumes, and elevated leukocyte counts were most predictive for death at 90 days.

FIGURE 2

Figure 2. Forest plot illustrating the univariate risk for poor clinical outcome (mRS > 2) and death at 90 days after mechanical thrombectomy in (A, B). (C) depicts the respective odds ratios in a multivariate model in patients with elevated CRP values. OR, odds ratio.

Due to the partial unavailability of confounding covariates, multivariate analysis and moderation analysis were calculated for a patient subset of n = 212.

Multivariate logistic regression, after correction for the effects of age, sex, atrial fibrillation, hypertension, diabetes mellitus, infarct volumes, pre-existing neurological impairments, and thrombectomy outcomes, highlights that initial CRP levels remained predictive for both mortality and poor mid-term outcome with respective odds ratios of 2.72 (95% CI: 1.43; 5.21) and 3.85 (95% CI: 2.49; 5.94), as shown in Figure 2C.

In a second step, the impact of the etiological subgroups with and without atrial fibrillation on the association between initial CRP levels and poor mid-term outcomes was tested in a moderation analysis under consideration of the abovementioned covariates. The conditional effect of initial CRP levels on poor outcomes remained significant for the atrial fibrillation group (p < 0.001). For the patient subgroup without atrial fibrillation, the conditional effect was lowered and lost its significance on the 5% level (p = 0.06), which implies that the importance of CRP levels for clinical outcomes is predominantly seen in patients with atrial fibrillation.

Multivariate logistic regression analyses for leukocyte counts lost their predictive power with respective odds ratios to predict mortality and poor mid-term outcomes of 0.92 (95% CI: 0.41, 2.05) and 0.73 (95% CI: 0.44, 1.23), respectively.

CRP values were further validated as a binary classifier for poor outcomes as a predictive model containing the above-referenced risk factors benefitted significantly from the inclusion of CRP measurements. As such, the AUC under the ROC increased from 0.74 (95% CI: 0.67, 0.81) to 0.81 (95% CI: 0.76, 0.87), as illustrated in Supplementary Figure 1. Calculation of the Youden Index yielded an optimal cutoff CRP level of 3.5 mg/l (sensitivity of 81.4% and specificity of 61%) and 8.5 mg/l (sensitivity of 69.0% and specificity of 69.0%) to predict poor outcomes and mortality, respectively.

Endpoint-dependent CRP analysis

Post-hoc determination of CRP levels as a function of outcome showed that patients who reached the endpoint of mortality or mRS > 2 did not only have higher CRP levels ad initio but also experienced prolonged increases in CRP levels over the first 7 days post-MT. Endpoint-dependent CRP trajectories and values are given in Figure 3.

FIGURE 3

Figure 3. Post-hoc determination of CRP dynamics as a function of outcomes. Beyond the initial increase of inflammatory markers in patients with poor outcomes, the trajectory of CRP values continued to steepen over the consecutive 7 days after MT as compared to the cohort with favorable outcomes. The upper panel depicts the respective trajectories of CRP values for patients with good outcomes (mRS ≤ 2), poor outcomes (mRS > 2), and mortality. The corresponding median values and respective 95% CI are given in the lower panel. *Significantly above mRS ≤ 2 at the respective timepoint.

Subgroup analysis for very-early inflammatory markers

In patients where initial blood sampling took place earlier than 4 h after symptom onset (n = 430), CRP levels were predictive for both poor outcomes [OR: 3.13 (95% CI, 2.06, 5.95)] and mortality [OR: 3.41 (95% CI, 2.11, 5.65)]. This effect remained intact in a multivariate model after correction for age, sex, atrial fibrillation, hypertension, diabetes mellitus, CTP-estimated infarct volume, premorbid mRS levels, NIHSS, and thrombectomy outcome for both poor clinical outcomes [OR: 2.59 (95% CI, 1.08, 6.41)] and mortality [OR: 2.94 (95% CI, 1.06, 9.07)]. Leukocyte counts, on the other hand, lost their predictive power for poor clinical outcomes after multivariate correction (Table 3).

TABLE 3

Table 3. Subgroup analysis for very-early (< 4 h after symptom onset) CRP levels and leukocyte counts to predict mortality or poor clinical outcomes.

Discussion

The present study validates systemic inflammation markers, especially CRP levels, for predicting clinical outcomes in a large collective of endovascularly treated stroke patients. Our results show that (i) poor outcome and death occur significantly more often in stroke patients with elevated CRP levels before MT, particularly in patients with atrial fibrillation, (ii) these effects seem to be mediated by a systemic inflammatory environment and not as a response to brain tissue ischemia, and (iii) the ischemia-inflammation cascade in MT patients is more pronounced if CRP levels are elevated ad initio.

Evidence is growing that systemic inflammation has a pivotal role in many pathophysiological processes from cardiovascular disease to cancer progression and cognitive decline (27–29). CRP has already been identified as a sensible serum marker to predict adverse outcomes in cardiovascular events, and its levels are known to be influenced by genetic polymorphisms, an observation that could further deepen our understanding of the development and progression of vascular disease (30). CRP as an inflammatory marker has been associated with atrial fibrillation, including development, recurrence, and total burden, as well as associated with thromboembolic complications (21). It thus seems plausible that inflammation also influences the pathogenesis of ischemic stroke.

In this study, we are interested in finding out whether CRP levels in the acute phase of ischemic stroke can help explain the outcome disparities in patients with endovascularly treated LVO.

Our data show that CRP levels at admission are strongly and independently associated with an increased risk of mortality and poor clinical outcomes. In a broad, prospectively acquired collective of 676 patients, we thus noted that 70% of deaths at 90-day follow-up occurred in patients with initially elevated CRP levels. Moreover, after multivariate correction for confounding factors known to carry a negative prognostic value such as reperfusion failure or large volumes of estimated infarct cores, the relative risk of death or poor clinical outcomes remains significant if CRP levels were elevated ad initio. This observation held true even as patients with elevated CRP levels had smaller infarct volumes as well as more favorable thrombectomy results than those with no signs of systemic inflammation. The influence of etiology was also deliberated while atrial fibrillation was chosen as a covariate. Despite the known association between atrial fibrillation and elevated CRP levels, the inflammation marker has independently impacted outcomes. In a moderation analysis, it was shown that the importance of CRP levels for clinical outcomes is predominantly seen in patients with atrial fibrillation. This fits the known association of CRP levels in atrial fibrillation with burden and severity of thromboembolic events. It may have an impact on clinical practice as special focus should be placed on patients with cardioembolic stroke and elevated CRP levels regarding rehabilitation and secondary prevention.

Furthermore, our observation that CRP trajectories post-MT diverge in a way that initially high levels tend to further increase over the course of 7 days is of particular interest. One could speculate that CRP promotes a cascade where first-hit tissue damage promotes inflammatory mechanisms, again worsening tissue damage through known effects such as complement activation or T-cell platelet interaction (15, 31). Secondary burn progression in thermic injuries, where cell necrosis advances beyond the initial stress area in a time-delayed manner, could thus be a blueprint for some of the pathophysiological processes in brain ischemia. Moreover, the fact that injury in myocardial infarction has been mitigated by blocking CRP synthesis hints at the plausibility of such a cascade and causative role that CRP could have in the time-delayed cellular damage (32).

Validation of our findings in a multicentric setting could pave the way for interventional studies exploring CRP apheresis as a possible tool to break this ischemia-inflammation cascade in stroke patients (32, 33). Elegantly, this could potentially be achieved through intensified statin use, as one of the lipid-lowering agent properties is to dose-dependently reduce levels of not only LDL—known to also negatively impact the prognosis of ischemic stroke patients—but also CRP and other inflammatory markers (34). The hypothesis that in adjunct to reducing established cardio- and cerebrovascular risk factors, mitigating low-level systemic inflammation as a means of primary and secondary prevention gains momentum as a promising future avenue in stroke care (35).

Although CRP has been validated as an independent predictor of poor outcomes in patients with ICH (36), we found no correlation between early CRP levels and brain hemorrhage or repeated LVO after MT. At first sight, this may seem counterintuitive given the vast evidence that links low-level inflammation to endothelial dysfunction and might be due to the overall low rates of these secondary endpoints in our study cohort (37). Moreover, leukocyte counts on admission carried less prognostic weight as this marker reacts more slowly to a pro-inflammatory stimulus and might thus be less well suited as an early predictive marker.

Testing for CRP-related genetic polymorphisms would have provided a significant value to our analysis as this could have clarified if CRP is really the hallmark agent linked to poor outcomes after MT or just a surrogate marker for low-level systemic inflammation.

The study design in its very nature was retrospective with all inherent limitations. A further limitation is the monocentric study setting, calling for prospective multicentric studies to validate our findings, as well as the multivariate analysis with less power due to the partial unavailability of confounding variables. All-cause mortality after 90 days was chosen as an endpoint due to the common impossibility to determine a specific cause of death, especially in a cohort of elderly patients. It can, however, be assumed that the large cohort size flattens out potential inequalities in the rates of confounding co-morbidities among both groups. Body temperatures were not available although this metric might have provided further information on the potential onset of a latent infection during the clinical stay. Moreover, definite volumes of the infarcted tissue were not quantitatively assessed. Finally, patients with elevated CRP levels were on average 3 years older, with intuitive prognostic implications, a confounder mitigated by the multivariate correction we performed in our analysis.

To conclude, our study provides evidence for the negative prognostic value of acute-stage CRP levels in stroke patients treated via MT. In a set of more than 600 patients, we show that mid-term clinical outcomes and mortality are significantly and independently associated with initial CRP levels, particularly in patients suffering from atrial fibrillation. Our findings encourage the theory that mitigating low-level systemic inflammation could be a promising step to improve the prognosis of stroke patients. Based on this, data questions on acute vs. chronic and systemic inflammation should be further investigated in larger studies.

Data availability statement

The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the datasets should be directed to TF, dG9tLmZpbmNrJiN4MDAwNDA7dHVtLmRl.

Ethics statement

The studies involving human participants were reviewed and approved by Local Ethics Committee. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2023.1167549/full#supplementary-material

Abbreviations

LVO, large-vessel occlusion; MT, mechanical thrombectomy; CRP, C-reactive protein; NIHSS, National Institutes of Health Stroke Scale; SNI, substantial neurological improvement; mRS, modified Rankin scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; tPA, tissue-type plasminogen activator; CTP, CT perfusion; SD, standard deviation; ROC, receiver operator characteristic; OR, odds ratio; CI, confidence interval.

References

1. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. (2015) 372:1019–30. doi: 10.1056/NEJMoa1414905

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. (2015) 372:2285–95. doi: 10.1056/NEJMoa1415061

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Campbell BCV, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. (2015) 372:1009–18. doi: 10.1056/NEJMoa1414792

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. (2015) 372:2296–306. doi: 10.1056/NEJMoa1503780

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Berkhemer OA, Fransen PS, Beumer D, Van Den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. (2015) 372:11–20. doi: 10.1056/NEJMx140064

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. (2018) 378:708–18. doi: 10.1056/NEJMoa1713973

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Menon BK, Hill MD, Davalos A, Roos YBWEM, Campbell BCV, Dippel DWJ, et al. Efficacy of endovascular thrombectomy in patients with M2 segment middle cerebral artery occlusions: meta-analysis of data from the HERMES Collaboration. J Neurointerv Surg. (2019) 11:1065–9. doi: 10.1136/neurintsurg-2018-014678

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Mensah GA, Norrving B, Feigin VL. The global burden of stroke. Neuroepidemiology. (2015) 45:143–5. doi: 10.1159/000441082

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. (2007) 38:967–73. doi: 10.1161/01.STR.0000258112.14918.24

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Pedersen A, Stanne TM, Nilsson S, Klasson S, Rosengren L, Holmegaard L, et al. Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. J Neurol. (2019) 266:2796–806. doi: 10.1007/s00415-019-09477-9

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Kent SM, Taylor AJ. Usefulness of lowering low-density lipoprotein cholesterol to < 70 mg/dl and usefulness of C-reactive protein in patient selection. Am J Cardiol. (2003) 92:1224–7. doi: 10.1016/j.amjcard.2003.07.040

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Arthurs ZM, Andersen C, Starnes BW, Sohn VY, Mullenix PS, Perry J. A prospective evaluation of C-reactive protein in the progression of carotid artery stenosis. J Vasc Surg. (2008) 47:744–50; discussion 751 doi: 10.1016/j.jvs.2007.11.066

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Montaner J, Fernandez-Cadenas I, Molina CA, et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke. (2006) 37:1205–10. doi: 10.1161/01.STR.0000217744.89208.4e

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. (2002) 347:1557–65. doi: 10.1056/NEJMoa021993

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Stoll G, Nieswandt B. Thrombo-inflammation in acute ischaemic stroke - implications for treatment. Nat Rev Neurol. (2019) 15:473–81. doi: 10.1038/s41582-019-0221-1

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Huber T, Kleine JF, Kaesmacher J, Bette S, Poppert H, Zimmer C, et al. Blood leukocytes as prognostic parameter in stroke thrombectomy. Cerebrovasc Dis. (2016) 42:32–40. doi: 10.1159/000444369

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol. (1974) 112:2135–47. doi: 10.4049/jimmunol.112.6.2135

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD, Harken AH. Diagnostic implications of C-reactive protein. Arch Surg. (2003) 138:220–4. doi: 10.1001/archsurg.138.2.220

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Hsuchou H, Kastin AJ, Mishra PK, Pan W. C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem. (2012) 30:1109–19. doi: 10.1159/000343302

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Laggner M, Lingitz M-T, Copic D, Direder M, Klas K, Bormann D, et al. Severity of thermal burn injury is associated with systemic neutrophil activation. Sci Rep. (2022) 12:1654. doi: 10.1038/s41598-022-05768-w

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Korantzopoulos P, Letsas KP, Tse G, Fragakis N, Goudis CA, Liu T. Inflammation and atrial fibrillation: a comprehensive review. J Arrhythm. (2018) 34:394–401. doi: 10.1002/joa3.12077

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. (2020) 395:878–87. doi: 10.1016/S0140-6736(20)30258-0

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org. 10172 in Acute Stroke Treatment. Stroke. (19943) 24:35–41. doi: 10.1161/01.STR.24.1.35

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver JL, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke. (2013) 44:2650–63. doi: 10.1161/STROKEAHA.113.001972

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Mokin M, Levy EI, Saver JL, Siddiqui AH, Goyal M, Bonafé A, et al. Predictive value of RAPID assessed perfusion thresholds on final infarct volume in SWIFT PRIME (solitaire with the intention for thrombectomy as primary endovascular treatment). Stroke. (2017) 48:932–8. doi: 10.1161/STROKEAHA.116.015472

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Hayes AF, Rockwood NJ. Regression-based statistical mediation and moderation analysis in clinical research: observations, recommendations, and implementation. Behav Res Ther. (2017) 98:39–57. doi: 10.1016/j.brat.2016.11.001

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Tao Q, Ang TFA, Akhter-Khan SC, Itchapurapu IS, Killiany R, Zhang X, et al. Impact of C-reactive protein on cognition and Alzheimer disease biomarkers in homozygous apolipoprotein E varepsilon4 carriers. Neurology. (2021) 97:e1243–52. doi: 10.1212/WNL.0000000000012512

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Hart PC, Rajab IM, Alebraheem M, Potempa LA. C-reactive protein and cancer-diagnostic and therapeutic insights. Front Immunol. (2020) 11:595835. doi: 10.3389/fimmu.2020.595835

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Blake GJ, Ridker PM. C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol. (2002) 22:1512–3. doi: 10.1161/01.ATV.0000038145.59548.85

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol. (2003) 23:2063–9. doi: 10.1161/01.ATV.0000084640.21712.9C

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Suresh MV, Singh SK, Ferguson DA Jr, Agrawal A. Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol. (2006) 176:4369–74. doi: 10.4049/jimmunol.176.7.4369

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Ries W, Torzewski J, Heigl F, Pfluecke C, Kelle S, Darius H, et al. C-reactive protein apheresis as anti-inflammatory therapy in acute myocardial infarction: results of the CAMI-1 study. Front Cardiovasc Med. (2021) 8:591714. doi: 10.3389/fcvm.2021.591714

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Boljevic D, Nikolic A, Rusovic S, Lakcevic J, Bojic M, Balint B, et al. Promising innovative treatment for ST-elevation myocardial infarction: the use of C-reactive protein selective apheresis: case report. Blood Purif. (2020) 49:753–7. doi: 10.1159/000506176

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. (2005) 352:29–38. doi: 10.1056/NEJMoa042000

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Ishikawa J, Tamura Y, Hoshide S, Eguchi K, Ishikawa S, Shimada K, et al. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. Stroke. (2007) 38:911–7. doi: 10.1161/01.STR.0000258115.46765.f1

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Löppönen P, Qian C, Tetri S, Juvela S, Huhtakangas J, Bode MK, et al. Predictive value of C-reactive protein for the outcome after primary intracerebral hemorrhage. J Neurosurg. (2014) 121:1374–9. doi: 10.3171/2014.7.JNS132678

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, et al. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. (2008) 201:318–25. doi: 10.1016/j.atherosclerosis.2008.02.034

PubMed Abstract | CrossRef Full Text | Google Scholar